<table>
<thead>
<tr>
<th>Study Title</th>
<th>Sponsor/Government Funding</th>
<th>Study Phase</th>
<th>Study Design</th>
<th>Study Population</th>
<th>Primary Endpoint</th>
<th>Start Date</th>
<th>End Date</th>
<th>cervenry</th>
<th>Study No</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alzheimer's Disease Ongoing Trials 2013</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>A 52-week, Placebo-controlled, Multicentre, Double-blind, Parallel-group</td>
<td>Eli Lilly</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2014 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Open-label, Randomised, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Double-blind, Placebo-controlled, Parallel-group</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01529619 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
<tr>
<td>A 12-month, Multicentre, Placebo-controlled, Parallel-group study</td>
<td>CENA713DTW04 (Novartis)</td>
<td>Active</td>
<td>Randomised</td>
<td>Early Alzheimer's</td>
<td>Alzheimer's Disease Assessment Scale cognitive subpart</td>
<td>01 Sep 2013 (planned)</td>
<td>01 Nov 2014 (planned)</td>
<td>Novartis, Ono Pharmaceutical</td>
<td>NCT01585272 (ClinicalTrials.gov: US National Institutes of Health)</td>
</tr>
</tbody>
</table>
Drug-utilisation

Cerebral-blood-flow

Cognitive function tests

Recruiting

Assessment scale scores

Assessment scale scores

Mini Mental State Examination

700192027 (Clinical Trials Insight), Neuropsychiatric Inventory baseline comparison prospective Abnormal Involuntary Movement Scale Amyloid levels 10 Jun 2011 (planned) 01 Feb 2012 (actual) 01 Dec 2015 (planned) Cognitive function tests Mini Mental State Examination 01 May 2012 (planned) Mini-Mental-State-Examination Medical-Outcome-Study-Short-Form-36 baseline comparison baseline comparison drug comparison Recruiting Active, no longer recruiting Mini-Mental-State-Examination Barnes-Akathisia-Scale 01 Sep 2011 (actual) Alzheimer's Disease Assessment Scale cognitive Neuropsychiatric Inventory drug regimen comparison Mini-Mental-State-Examination Abnormal-Involuntary-Movement-Scale Cognitive-function-tests 700056545 (Clinical Trials Insight), baseline comparison Cognitive-function-tests Physician-assessment Receptor occupancy Inflammatory-markers 01 Nov 2017 (planned) randomised Hopkins-Verbal-Learning-Test 01 Aug 2006 (actual) parallel patient comparison 700005197 (Clinical Trials Insight), Active, no longer recruiting Bristol Activities of Daily Living Scale Cerebral blood flow Assessment scale scores Neuropsychiatric-Inventory Cognitive-function-tests Brain-derived-neurotrophic-factor-levels patient comparison 700213849 (Clinical Trials Insight), Clinical response rate Motor function Mini-Mental-State-Examination prospective 01 Jul 2013 (planned) 01 Apr 2012 (actual) Alzheimer's Disease Assessment Scale Cerebral blood flow double-blind 700206791 (Clinical Trials Insight), placebo comparison multicentre 01 Jan 2012 (actual) Active, no longer recruiting baseline comparison Recruiting

A Multi-Center Randomized Placebo-Controlled, Parallel-Group phase 3 study to assess the efficacy and safety of Donepezil Hydrochloride in Chinese Subjects With Severe Alzheimer's Disease.


The treatment of dementia with Doxycycline.

Brexpiprazole.

Rivastigmine.

Memantine.

Donepezil.

Nilvadipine.

Clinical Dementia Rating.

Alzheimer's Disease Assessment Scale.

Activities of Daily Living Inventory.

Quality of life instrument.

Inflammatory markers.

Vital signs.

Pulse rate.

Mini Mental State Examination.

Laboratory parameters.

Computed tomography.

Symptoms.

Neuropsychiatric Inventory.

Magnetic resonance imaging outcomes.

Global Impression of Change.

Cognitive function tests.

Alzheimer's-Disease-Assessment-Scale-cognitive-subpart.

Treatment-discontinuation.

Archer Pharmaceuticals.

Accera.

Clinical Global Impressions scale.

Drug concentration.

placebo comparison.

Alzheimer's Disease Cooperative Study Activities.

Recruiting.

Drug combination comparison.

Biomarker levels.

drug comparison.

Drug dosage comparison.

Disability Assessment for Dementia.

Apathy-Evaluation-Scale.
<table>
<thead>
<tr>
<th>Organization</th>
<th>Drug Study Title</th>
<th>Study Type</th>
<th>Start Date</th>
<th>End Date</th>
<th>Primary Endpoint</th>
<th>Secondary Endpoints</th>
</tr>
</thead>
<tbody>
<tr>
<td>BELLUS Health</td>
<td>1RO1AG033133-01A1 (Seattle Alzheimer's Disease Cooperative Study Activities)</td>
<td>placebo comparison</td>
<td>01 Dec 2012 (planned)</td>
<td>01 Dec 2013 (planned)</td>
<td>drug vs drug + nondrug comparison</td>
<td>Cognitive function tests</td>
</tr>
<tr>
<td>Eli Lilly</td>
<td>700234734 (Clinical Trials Insight)</td>
<td>baseline comparison</td>
<td>01 Mar 2007 (actual)</td>
<td>01 Jun 2011 (actual)</td>
<td>placebo comparison</td>
<td>Positive-and-Negative-Syndrome-Scale</td>
</tr>
<tr>
<td>Novartis</td>
<td>Planning - Recruiting - Not yet recruiting</td>
<td>baseline comparison</td>
<td>01 May 2007 (planned)</td>
<td>01 Jun 2016 (planned)</td>
<td>patient comparison</td>
<td>Alzheimer's Disease Assessment Scale</td>
</tr>
<tr>
<td>Eisai Korea</td>
<td>ECG-changes</td>
<td>placebo comparison</td>
<td>01 Dec 2013 (planned)</td>
<td>01 Dec 2013 (planned)</td>
<td>drug combination comparison</td>
<td>Clinical Global Impressions scale</td>
</tr>
<tr>
<td>TransTech Pharma</td>
<td>700006205 (Clinical Trials Insight)</td>
<td>baseline comparison</td>
<td>01 Dec 2013 (planned)</td>
<td>01 Dec 2013 (planned)</td>
<td>patient comparison</td>
<td>Cost:effectiveness ratio</td>
</tr>
<tr>
<td>Lundbeck A/S</td>
<td>Planning - Recruiting - Not yet recruiting</td>
<td>baseline comparison</td>
<td>01 Dec 2013 (planned)</td>
<td>01 Dec 2013 (planned)</td>
<td>double-blind</td>
<td>Alzheimer's Disease Assessment Scale</td>
</tr>
<tr>
<td>Takeda Pharmaceuticals USA</td>
<td>Planning - Recruiting - Not yet recruiting</td>
<td>baseline comparison</td>
<td>01 Dec 2013 (planned)</td>
<td>01 Dec 2013 (planned)</td>
<td>parallel</td>
<td>Alzheimer's Disease Assessment Scale</td>
</tr>
</tbody>
</table>

**Endpoints:***
- Alzheimer's Disease Assessment Scale cognitive function tests
- Positive-and-Negative-Syndrome-Scale
- Alzheimer's Disease Assessment Scale cognitive function tests
- Amyloid levels
- Clinical Global Impressions scale
- Cognitive function tests
- Alzheimer's Disease Assessment Scale
- Mini-Mental-State-Examination
- Blood pressure
- Not yet recruiting
- double-blind
- Recruiting
- Not yet recruiting
- parallel
MK-8931 in Subjects With Mild to Moderate Alzheimer's Disease.

A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 12-Month Trial of Leucoalbumin-human Immune-globulin as Add-on Therapy to Rivastigmine Patch for the Treatment of Asymptomatic Alzheimer's Disease.

Evaluate the Efficacy and Safety of Short-Term Plasma Exchange Followed by Long-Term Prazosin Treatment for Disruptive Agitation in Alzheimer Disease.

Label Extension for Solanezumab and Gantenerumab in Subjects With Mild to Moderate Alzheimer's Disease.

Diagnosis of Inherited Alzheimer's Disease: A 26-Week, Double-blind, Randomized, Placebo-Controlled, Parallel-Group, Subpart 3 Study in the Effect of Citrus Reticulata peels on Alzheimer's Disease.

Eisai Inc. Clinical Trials Insight, 700225727 (Clinical Trials Insight), 700223431 (Clinical Trials Insight), 700214175 (Clinical Trials Insight), 700215366 (Clinical Trials Insight), 700194490 (Clinical Trials Insight), 700193943 (Clinical Trials Insight), 700193689 (Clinical Trials Insight), 9931-017, DIAN-TU001 (Washington University School of Medicine, National Institutes of Health), NCT01739348 (ClinicalTrials.gov: US National Institutes of Health), EudraCT2012-002866-11 (European Clinical Trials Database), 362812 (Australian Pharmaceutical Co.), NCT01282619 (ClinicalTrials.gov: US National Institutes of Health), TRx237-017-01 (Merck and Co.), NCT017-02, MK8931-017-03 (Merck and Co.), NCT01670526 (ClinicalTrials.gov: US National Institutes of Health), 8931-017, 8931-017-04 (Merck and Co.), NCT01539031 (ClinicalTrials.gov: US National Institutes of Health), NCT01689246 (ClinicalTrials.gov: US National Institutes of Health), NCT01463572 (European Clinical Trials Database), NCT01282619 (ClinicalTrials.gov: US National Institutes of Health).
<table>
<thead>
<tr>
<th>Trial ID</th>
<th>Title</th>
<th>Sponsor</th>
<th>Status</th>
<th>Start Date</th>
<th>End Date</th>
<th>Indication</th>
<th>Primary Outcomes</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT01852110</td>
<td>IRIS - A Phase II Study to Evaluate the Efficacy and Safety of Rivastigmine in Patients with Moderate to Severe Alzheimer's Disease</td>
<td>Eisai Inc.</td>
<td>Active, recruiting</td>
<td>01 Jul 2011</td>
<td>01 Aug 2012</td>
<td>Alzheimer's Disease</td>
<td>Efficacy and safety of Rivastigmine compared to placebo in patients with moderate to severe AD</td>
</tr>
<tr>
<td>NCT01767311</td>
<td>A Phase IIb, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Drug Combinations</td>
<td>Merck</td>
<td>Active, recruiting</td>
<td>01 Sep 2014</td>
<td>30 Nov 2014</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different drug combinations in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01677754</td>
<td>A Randomized, Controlled, Parallel Group, Double-Blind, Multi-center, Phase II Study to Assess the Safety and Tolerability of Different Route of Administration Comparisons</td>
<td>Hoffmann-La Roche</td>
<td>Active, recruiting</td>
<td>01 Oct 2013</td>
<td>31 Dec 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different route of administration comparisons in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01532110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Clinical Activity of Continued AFFITOPE in Subjects with Mild-To-Moderate Alzheimer's Disease</td>
<td>AFFiRiS</td>
<td>Active, recruiting</td>
<td>19 Nov 2012</td>
<td>18 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and clinical activity of continued AFFITOPE in subjects with moderate AD</td>
</tr>
<tr>
<td>NCT01422110</td>
<td>A Randomized, Controlled, Parallel Group, Double-Blind, Multi-center, Phase II Study to Assess the Safety and Tolerability of Different Drug Dosage Comparisons</td>
<td>Pfizer</td>
<td>Active, recruiting</td>
<td>01 Dec 2010</td>
<td>31 Jan 2012</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different drug dosage comparisons in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01372110</td>
<td>A Randomized, 18-Week, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of PF-05212377 (SAM-760) in Patients with Mild-to-Moderate Alzheimer's Disease</td>
<td>Genentech</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Efficacy and safety of PF-05212377 (SAM-760) in patients with mild-to-moderate AD</td>
</tr>
<tr>
<td>NCT01322110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Antibody Levels in Patients with Moderate Alzheimer's Disease</td>
<td>Wyeth Pharmaceuticals</td>
<td>Active, recruiting</td>
<td>01 Dec 2016</td>
<td>31 Jan 2017</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different antibody levels in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01272110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Biomarker Levels in Patients with Moderate Alzheimer's Disease</td>
<td>Genentech</td>
<td>Active, recruiting</td>
<td>01 Dec 2016</td>
<td>31 Jan 2017</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different biomarker levels in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01222110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Merck</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01172110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Laboratory Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Pfizer</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different laboratory parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01122110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Genentech</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01072110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Wyeth Pharmaceuticals</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01022110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Pfizer</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01012110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Genentech</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
<tr>
<td>NCT01002110</td>
<td>A Randomized, Double-Blind, Placebo Controlled, Parallel Group Study to Evaluate the Safety and Tolerability of Different Clinical Parameters in Patients with Moderate Alzheimer's Disease</td>
<td>Wyeth Pharmaceuticals</td>
<td>Active, recruiting</td>
<td>01 Nov 2012</td>
<td>30 Jan 2013</td>
<td>Alzheimer's Disease</td>
<td>Safety and tolerability of different clinical parameters in patients with moderate AD</td>
</tr>
</tbody>
</table>

**Primary Outcomes**
- **Mini Mental State Examination**
- **Immunoglobulin G levels**
- **Magnetic resonance imaging outcomes**
- **Laboratory parameters**
- **Quality of life**
- **Protein levels**
- **Mini Mental State Examination**
- **Global Deterioration Scale**
- **Rating Scale**
- **Neuropsychiatric Inventory**
- **Magnetic resonance imaging outcomes**
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Design</th>
<th>Primary Outcome</th>
<th>Reporting Status</th>
<th>Baseline Comparison</th>
<th>Drug Formulation Comparison</th>
<th>Time to Peak Drug Concentration</th>
<th>Route of Administration Comparison</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Neuropsychiatric Inventory</strong></td>
<td>Planning</td>
<td>Cognitive-function-tests</td>
<td>01 Sep 2010 (planned)</td>
<td>placebo comparison</td>
<td>Planning</td>
<td>22 Jun 2009 (actual)</td>
<td>GlaxoSmithKline</td>
</tr>
<tr>
<td><strong>Cornell Scale for Depression in Dementia</strong></td>
<td>01 Jun 2009 (planned)</td>
<td>Drug formulation comparison</td>
<td>Baseline comparison</td>
<td>Drug combination comparison</td>
<td>Time-to-peak-drug-concentration</td>
<td>700029331 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Columbia Suicide Severity Rating Scale</strong></td>
<td>07 Jan 2008 (actual)</td>
<td>ECG changes</td>
<td>Recruiting</td>
<td>25 Sep 2012 (planned)</td>
<td>GlaxoSmithKline</td>
<td>700206046 (Clinical Trials Insight), 700007433 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Positron emission tomography imaging outcomes</strong></td>
<td>Allon Therapeutics</td>
<td>Biomarker levels</td>
<td>Recruiting</td>
<td>GlaxoSmithKline</td>
<td>recruiting</td>
<td>700058583 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Mini Mental State Examination</strong></td>
<td>Recruitment</td>
<td>Area-under-the-drug-concentration-time-curve</td>
<td>Recruiting</td>
<td>700041103 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700054973 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Computerised tomography changes</strong></td>
<td>Planning</td>
<td>Drug dosage comparison</td>
<td>Recruiting</td>
<td>700056729 (Clinical Trials Insight), SB-742457</td>
<td>GlaxoSmithKline</td>
<td>700031053 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Alzheimer's Disease Assessment Scale</strong></td>
<td>Recruitment</td>
<td>Laboratory parameters</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Genentech, Roche</strong></td>
<td>Recruitment</td>
<td>Laboratory parameters</td>
<td>Recruiting</td>
<td>700056729 (Clinical Trials Insight), SB-742457</td>
<td>GlaxoSmithKline</td>
<td>700031053 (Clinical Trials Insight), Dendron073</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Carvedilol as a potential novel disease modifying intervention</strong></td>
<td>Recruitment</td>
<td>Activities of Daily Living Scale</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>Healthy Volunteers to Evaluate the Relative Potency of Immediate Release Formulation of Huperzine A Compared with Controlled Release Formulations of Huperzine A</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Prototype Comparison of Davunetide and Placebo in Subjects with Non-Alzheimer's Disease with Cognitive Disturbances</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Placebo-Controlled, Double-Blind, Crossover Study to Evaluate the Safety, Tolerability and Efficacy of a Novel Anticholinesterase Agent, ABT-126, in Subjects with Alzheimer's Disease with Cognitive Disturbances</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of SB-742457 as an Adjunctive Therapy for Patients with Alzheimer's Disease with Cognitive Disturbances</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>An Open Label Extension Study to Assess the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Prospective Parallel Group Study to Evaluate the Efficacy of ABT-126 for Mild to Moderate Alzheimer's Disease</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Prospective Parallel Group Study to Evaluate the Efficacy of ABT-126 for Mild to Moderate Alzheimer's Disease</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
<tr>
<td><strong>A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of ABT-126 in Subjects With Mild to Moderate Alzheimer's Disease</strong></td>
<td>Recruitment</td>
<td>Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors</td>
<td>Recruiting</td>
<td>700030491 (Clinical Trials Insight)</td>
<td>GlaxoSmithKline</td>
<td>700028325 (Clinical Trials Insight)</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>

**Notes:**
- **ClinicalTrials.gov:** US National Institutes of Health
- **DRKS00003133:** German Clinical Trials Database
- **EudraCT:** European Clinical Trials Database
- **NCT:** National Institutes of Health Clinical Trials Database
<table>
<thead>
<tr>
<th>Study Title</th>
<th>Disease Area</th>
<th>Study Type</th>
<th>Intervention</th>
<th>Comparator</th>
<th>Recruitment Status</th>
<th>Start Date</th>
<th>End Date</th>
<th>Registration Numbers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Efficacy of NK 001 [etanercept] for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Nondrug</td>
<td>Drug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>06 Sep 2012</td>
<td>NCT00238589 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-26 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Efficacy and Safety of Tamibarotene (OAM80) for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Drug</td>
<td>Nondrug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>21 Feb 2014</td>
<td>NCT00637442 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-27 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Efficacy and safety of 3 doses of S 38093 (2, 5 and 10 mg/day) for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Drug</td>
<td>Placebo</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>26 May 2011</td>
<td>NCT00338891 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-31 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Efficacy and Safety of Bacopa monnieri for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Nondrug</td>
<td>Drug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>01 Dec 2014</td>
<td>NCT00382056 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-32 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Efficacy of the association between an inhibitor of matrix metalloproteinase (MMPP) and the precursory of the cholinergic system for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Drug</td>
<td>Nondrug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>01 Dec 2014</td>
<td>NCT00382056 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-35 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Effect of the association between an inhibitor of Tau levels and the precursory of the cholinergic system for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Drug</td>
<td>Nondrug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>01 Dec 2014</td>
<td>NCT00382056 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-36 (European Clinical Trials Database)</td>
</tr>
<tr>
<td>Effect of Treatment With Doxycycline and Bacopa monnieri for the Treatment of Alzheimer's Disease</td>
<td>Alzheimer's Disease</td>
<td>Randomised</td>
<td>Drug</td>
<td>Nondrug</td>
<td>Recruiting</td>
<td>01 Mar 2013</td>
<td>01 Dec 2014</td>
<td>NCT00382056 (ClinicalTrials.gov: US National Institutes of Health), OAM80-005841-37 (European Clinical Trials Database)</td>
</tr>
</tbody>
</table>

**Notes:**
- "Recruiting" indicates active recruitment as of the last update.
- "No longer recruiting" indicates recruitment has ended.
- "Placebo comparison" indicates a comparison with placebo.
- "Baseline comparison" indicates baseline comparison.
- "Drug dosage comparison" indicates comparison with a different drug dosage.
- "Double-blind" indicates a double-blind study.
- "Parallel" indicates a parallel group design.

**Registration Numbers:**
- NCT00238589 (ClinicalTrials.gov: US National Institutes of Health)
- NCT00637442 (ClinicalTrials.gov: US National Institutes of Health)
- OAM80-005841-26 (European Clinical Trials Database)
- OAM80-005841-27 (European Clinical Trials Database)
- OAM80-005841-31 (European Clinical Trials Database)
- OAM80-005841-32 (European Clinical Trials Database)
- OAM80-005841-33 (European Clinical Trials Database)
- OAM80-005841-34 (European Clinical Trials Database)
- OAM80-005841-35 (European Clinical Trials Database)
- OAM80-005841-36 (European Clinical Trials Database)
- OAM80-005841-37 (European Clinical Trials Database)
- OAM80-005841-38 (European Clinical Trials Database)
- OAM80-005841-39 (European Clinical Trials Database)
- OAM80-005841-40 (European Clinical Trials Database)
- OAM80-005841-41 (European Clinical Trials Database)
- OAM80-005841-42 (European Clinical Trials Database)
- OAM80-005841-43 (European Clinical Trials Database)
- OAM80-005841-44 (European Clinical Trials Database)
- OAM80-005841-45 (European Clinical Trials Database)
- OAM80-005841-46 (European Clinical Trials Database)
- OAM80-005841-47 (European Clinical Trials Database)
baseline comparison

Neuropsychiatric-Inventory

Mini Mental State Examination

Maximum tolerated dose

Antibody levels

Area under the drug concentration time curve

Assessment scale scores

Zinc monocysteine in elderly patients with mild to

700190904 (Clinical Trials Insight),

drug combination comparison

Janssen Research & Development

Recruiting

700050142 (Clinical Trials Insight),

Alzheimer's-Disease-Assessment-Scale-cognitive-subpart

Assessment scale scores

01 Sep 2012 (planned)

Immunological-response

Mini Mental State Examination

01 Mar 2013 (actual)

I/II

parallel

Janssen Research & Development

09 Dec 2012 (planned)

placebo comparison

Alzheimer's-Disease-Assessment-Scale

Mini Mental State Examination

ECG-changes

Area under the drug concentration time curve

01 Apr 2012 (actual)

prospective

Electrophysiological measures

Active, no longer recruiting

subject comparison

parallel

01 Jan 2008 (actual)

700055152 (Clinical Trials Insight),

Immunological response rate

Trail-Making-Test-Part-B

040686, 700019820 (Clinical Trials

Elimination rate constant

700215283 (Clinical Trials Insight),

Trail Making Test Part B

01 Aug 2013 (planned)

placebo comparison

II

16 May 2010 (planned)

Drug concentration

Cohen Mansfield Agitation Inventory

01 Mar 2014 (planned)

Computerised tomography changes

Recruiting

Inflammatory-markers

placebo comparison

700212560 (Clinical Trials Insight),

Biomarker levels

Area under the drug concentration time curve

Activities of Daily Living Scale

Letter and Category Fluency

Controlled Oral Word Association Test

Synthetic Biologics

Brain volume

Drug terminal half life

placebo comparison

233

230

226

225

214

212

A Multi-center, Parallel-group, Double-blind,

Following Subcutaneous Injection in Japanese AD

Tolerability and Pharmacokinetics of RO4909832

Randomized, Double-blind, Placebo-controlled,

A Multi-center, Multiple-ascending Dose,

Impairment

A Double-blind, Randomized, Placebo-controlled,

of AADvac1 Applied to Patients With Mild-

Phase I Study to Assess Tolerability and Safety

The role of the neurotransmitters dopamine and

Disease Efficacy trial

either donepezil or galantamine to rivastigmine

TTP-4000

JNJ-54861911

Isoflavones

Isotretinoin

Thioctic-acid

Bryostatin-1

RPh-201

Zinc-monocysteine

Rivastigmine

volunteers and patients with Alzheimer's disease.

Efficacy of Nicotinamide for the Treatment of

in Healthy Subjects and in Adults With

Evaluating the Safety and Tolerability of RPh201

A Randomized Single and Multiple Dose Study

Tolerability, Immunogenicity and Efficacy of ACI-

Dementia.

Two Phase, Repeated Crossover Study With Dose

Quality of Life in Alzheimers Disease Scale

Positron emission tomography imaging outcomes
Magnetic resonance imaging outcomes

Biomarker levels
- Amyloid levels: 15082 (Eli Lilly), 700232264 (Clinical Trials Insight), 700232406 (Clinical Trials Insight)
- Tau levels: 700210693 (Clinical Trials Insight), 700222669 (Clinical Trials Insight)

Columbia Suicide Severity Rating Scale
- Baseline comparison

Pharmacokinetic parameters
- Peak drug concentration: 01 Dec 2011 (actual), 01 Sep 2007 (actual)
- Area under the drug concentration time curve (AUC): 01 Feb 2012 (actual), 01 May 2013 (planned), 01 May 2013 (planned)
- Drug concentration
- Drug clearance
- Peak drug concentration: 01 Dec 2012 (actual)
- Drug metabolism
- Drug concentration: 01 Apr 2016 (planned)

Disability Assessment for Dementia
- Baseline comparison

Clinical Dementia Rating
- Placebo comparison

University of Tokyo

Antibody levels
- 01 Oct 2013 (planned)

Biomarker levels
- 01 Jun 2013 (planned)

Alzheimer's Disease Assessment Scale cognitive subpart
- 01 Mar 2015 (planned)

JANSSEN Alzheimer Immunotherapy, Pfizer
- Randomised, prospective, double-blind, placebo-controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics, and effect on biomarkers of AZD3293 including antibody levels.

AstraZeneca
- A Single-Centre, Double Blind, Randomized, Two-Part, Multiple Ascending Dose Controlled Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Effect of BMS-241027 on Antibody Levels in Patients With Mild to Moderate Alzheimer’s Disease

Eisai Co Ltd, Eisai Inc
- A randomised, double-blind, placebo-controlled, adaptive, multiple stage, parallel-group study to evaluate the safety, tolerability, pharmacokinetics of BIIB037 in healthy male and non-fertile female elderly subjects.

Amino-acid oxidase (AOX) oxidized forms of Alzheimer's disease-related proteins (AD-RP) are distinctively modified in Alzheimer's disease (AD).

AZD3480 Pharmacodynamic in Healthy Male Subjects
- A multi-centre, randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, and pharmacokinetic properties of AZD3480 given as an oral ingestion in patients with mild to moderate Alzheimer's disease.

AZD3480 and Warfarin and the Effect of Ispronicline Way Cross-Overs Study of Repeated Doses of AZD3480
- A single-centre, double-blind, randomised, two-part, multiple ascending dose controlled, single ascending dose study to assess the safety, tolerability, and pharmacokinetics of EVP-6124 and supratherapeutic concentrations following a single oral dose of E2609 in subjects with mild Alzheimer's disease.

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Of AAB-003 (PF-05236812) In Subjects With Mild To Moderate Alzheimer’s Disease
- An active, no longer recruiting, double-blind, placebo-controlled, adaptive, multiple stage, parallel-group study to evaluate the safety, tolerability, pharmacokinetics of AAB-003 given as an intravenous infusion or as subcutaneous injection in patients with mild to moderate Alzheimer's disease.

Long-term Safety and Tolerability of AAB-003 SAR228810 Given as IV Infusion or as SC注射 in Patients With Mild to Moderate Alzheimer's Disease
- An active, no longer recruiting, multicentre, randomised, double-blind, placebo-controlled, single and multiple dose, controlled, single ascending dose study to assess the safety, tolerability, pharmacokinetics of AAB-003 in subjects with mild to moderate Alzheimer's disease.

Mini Mental State Examination

Clinical Dementia Rating
- Placebo comparison

Recruiting
- 01 Jul 2009 (actual)
- 01 Dec 2011 (actual)
- 01 Mar 2015 (planned)
- 01 Sep 2007 (actual)
- 01 Dec 2011 (actual)
- 01 Sep 2010 (actual)
- 01 Jun 2014 (planned)
- 01 Oct 2013 (planned)
- 01 Feb 2012 (actual)
- 01 Sep 2007 (actual)